5268W-12 A Phase 2 Randomized, Controlled Study with a Phase 1 Safety Cohort testing ALD-401 Derived

A Phase 2 Randomized, Controlled Study with a Phase 1 Safety Cohort testing ALD-401 Derived from Autologous Bone Marrow Delivered via Intracarotid Infusion in Subjects with Ischemic Stroke with Blinded Assessments.

Type of Study
Neuroscience - Stroke
Short Description
To demonstrate the safety of the delivery of ALD-401 by intracarotid infusion in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle carotid artery (MCA).
 
Status
Open
Principal Investigator
William Likosky, MD
Eligibility Notes
Male and female subjects, age 30 to 83 years, who have had recent acute ischemic stroke in the middle cerebral artery (MCA) distribution confirmed by MRI or CT scan, within 24 hrs, has persistent neurological deficit, is able to provide bone marrow sample from anterior or posterior ileac crest at the time required by the protocol, and is able to return for dosing two days post bone marrow harvest.
 
Contact Name
Amanda Brown and Colleen Truva, RN
Phone
206-320-2604
Alternate Phone
206-215-3982
Email
amanda.brown@swedish.org
Alternate Email
colleen.truva@swedish.org